ArticleBMC neuroscience2010
Antillatoxin is a sodium channel activator that displays unique efficacy in heterologously expressed rNav1.2, rNav1.4 and rNav1.5 α subunits.
Article in BMC neuroscience, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 31 citations in OpenAlex.
- A High-Throughput Biosensing Approach for Rapid Screening of Compounds Targeting the hNav1.1 Channel: Marine Toxins as a Case Study.Marine drugs · 2025Article
- Voltage-Gated Sodium Channels: A Prominent Target of Marine Toxins.Marine drugs · 2021Review
- Manipulation-free cultures of human iPSC-derived cardiomyocytes offer a novel screening method for cardiotoxicity.Acta pharmacologica Sinica · 2018Article
- Sodium channels and pain: from toxins to therapies.British journal of pharmacology · 2018Review
- Mechanism-specific assay design facilitates the discovery of Nav1.7-selective inhibitors.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- A Maldiisotopic Approach to Discover Natural Products: Cryptomaldamide, a Hybrid Tripeptide from the Marine Cyanobacterium Moorea producens.Journal of natural products · 2017Article
- Development of a Rapid Throughput Assay for Identification of hNav1.7 Antagonist Using Unique Efficacious Sodium Channel Agonist, Antillatoxin.Marine drugs · 2016Article
- Biological targets and mechanisms of action of natural products from marine cyanobacteria.Natural product reports · 2015Review
- Recent progress in neuroactive marine natural products.Natural product reports · 2014Review
- Shellfish toxins targeting voltage-gated sodium channels.Marine drugs · 2013Review
- Marine cyanobacteria compounds with anticancer properties: a review on the implication of apoptosis.Marine drugs · 2012Review
- Neurotoxins and their binding areas on voltage-gated sodium channels.Frontiers in pharmacology · 2011Article
- Biologically active secondary metabolites from marine cyanobacteria.Current opinion in biotechnology · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundAntillatoxin (ATX) is a structurally unique lipopeptide produced by the marine cyanobacterium Lyngbya majuscula. ATX activates voltage-gated sodium channel α-subunits at an undefined recognition site and stimulates sodium influx in neurons. However, the pharmacological properties and selectivity of ATX on the sodium channel α-subunits were not fully characterized.
resultsIn this study, we characterized the pharmacological properties and selectivity of ATX in cells heterologously expressing rNa(v)1.2, rNa(v)1.4 or rNa(v)1.5 α-subunits by using the Na(+) selective fluorescent dye, sodium-binding benzofuran isophthalate. ATX produced sodium influx in cells expressing each sodium channel α-subunit, whereas two other sodium channel activators, veratridine and brevetoxin-2, were without effect. The ATX potency at rNa(v)1.2, rNa(v)1.4 and rNa(v)1.5 did not differ significantly. Similarly, there were no significant differences in the efficacy for ATX-induced sodium influx between rNa(v)1.2, rNa(v)1.4 and rNa(v)1.5 α-subunits. ATX also produced robust Ca²(+) influx relative to other sodium channel activators in the calcium-permeable DEAA mutant of rNa(v)1.4 α-subunit. Finally, we demonstrated that the 8-demethyl-8,9-dihydro-antillatoxin analog was less efficacious and less potent in stimulating sodium influx.
conclusionsATX displayed a unique efficacy with respect to stimulation of sodium influx in cells expressing rNa(v)1.2, rNa(v)1.4 and rNa(v)1.5 α-subunits. The efficacy of ATX was distinctive inasmuch as it was not shared by activators of neurotoxin sites 2 and 5 on VGSC α-subunits. Given the unique pharmacological properties of ATX interaction with sodium channel α-subunits, decoding the molecular determinants and mechanism of action of antillatoxin may provide further insight into sodium channel gating mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.